Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Andrew Lassman MD
Open to Accrual
August 6, 2020
Most Recent Amendment Date:
February 9, 2021
Phase II : To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation
Phase III : To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs overall survival (OS) versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation
Histopathologically proven diagnosis of glioblastoma (orgliosarcoma as a subtype of glioblastoma) confirmed by central pathology review. MGMT promoter without methylation confirmed by central pathology review. IDH mutation testing by at least one method must be performed as part of standard of care and no mutation must be found.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.